Trial Profile
Phase II Multi-centre, Double-Blind, Randomized, Placebo-Controlled Safety and Efficacy Study of Oral Recombinant Ovine Interferon-Tau (IFN-tau) Administered Daily in Patients with Relapsing-Remitting Multiple Sclerosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Jun 2016
Price :
$35
*
At a glance
- Drugs Interferon tau (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 30 Aug 2011 New trial record